Top Markets
#1 GEKKO GEKKO +50.71%
#2 Helium Helium +45.05%
#3 TENDIES TENDIES +44.18%
#4 ADO Protocol ADO Protocol +39.08%
#5 Pons Pons +36.21%
#6 Prom Prom +32.22%
#7 o1.exchange o1.exchange +21.80%
#8 StonkBroker StonkBroker +21.46%
#9 Collector Crypt Collector Crypt +20.52%
#10 Nillion Nillion +19.37%
Coin of the day
GEKKO GEKKO
Settings
Language
ENGLISH
Currency
USD
Theme
Orum Therapeutics, Inc. Orum Therapeutics, Inc.

Orum Therapeutics, Inc.

475830
Rank in Stocks #9664
Orum Therapeutics, Inc. is a biopharmaceutical company dedicated to the... Orum Therapeutics, Inc. is a biopharmaceutical company dedicated to the discovery and development of novel therapeutic solutions for both cancer and immune system conditions. The firm specializes in creating degrader-antibody conjugates, an innovative class of drugs that merges traditional antibody-drug conjugate (ADC) technology with targeted protein degradation. Their flagship product candidate, ORM-1153, functions as a GSPT1 protein degrader, specifically engineered to address hematologic malignancies. Orum Therapeutics was established in 2016 and operates out of Daejeon, South Korea.
Share Price
$45.64
Last synced: 2026-08-28
Market Cap
$969.02M
Change (1 day)
-1.20%
Change (1 year)
146.66%
Country
KR
Trade Orum Therapeutics, Inc. (475830)

Category

Healthcare
Revenue for Orum Therapeutics, Inc. (475830)
Revenue in Aug 2026 TTM: 0
According to Orum Therapeutics, Inc. latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Orum Therapeutics, Inc. from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH